Table 1.

Regimen of antiresorptive agents according to underlying bone disease

	Osteoporosis		CTIBL		Bone metastases
	Dose	Frequency	Dose	Frequency	Dose	Frequency
Bisphosphonates
Alendronate	70 mg by mouth	Weekly	70 mg by mouth	Weekly	–	–
Risedronate	35 mg (75 mg) by mouth	Weekly (2 consecutive d/mo)	35 mg by mouth	Weekly	–	–
Ibandronate	150 mg by mouth	Monthly	150 mg by mouth	Monthly	50 mg	Daily
	3 mg IV	Every 3 mo	–	–	6 mg IV	Every 3-4 wk
Pamidronate	–	–	60 mg IV	Every 3 mo	90 mg IV	Every 3-4 wk
Zoledronate	5 mg IV	Yearly	4 mg IV	Every 3-6 mo	4 mg iv	Every 3-4 wka
Denosumab	60 mg SC	Every 6 mo	60 mg SC	Every 6 mo	120 mg SC	Every 4 wk

Abbreviations: CTIBL, cancer treatment–induced bone loss; IV, intravenously; SC, subcutaneously.

^a At least for the first 3 to 6 months; de-escalation to doses every 12 weeks could be considered thereafter.